

ERRATA

Volume **276**, Number 2 (2000), in the article “Knockdown of Caveolin-1 by Antisense Oligonucleotides Impairs Angiogenesis *in Vitro* and *in Vivo*,” by Cristiana Griffoni, Enzo Spisni, Spartaco Santi, Massimo Riccio, Tiziana Guarnieri, and Vittorio Tomasi, pages 756–761 (doi:10.1006/bbrc.2000.3484): On page 759, Fig. 3, the lanes 4 and 5 were mislabeled at the top of the figure. They should be reversed. Lane 4 should read “ODN-4” and lane 5 should read “ODN-1.” The legend was also incorrect as printed. The last two lines of the legend should read “. . . lane 4, HUVEC treated with 0.5 μ M ODN 4 (antisense ODN); lane 5, HUVEC treated with 0.5 μ M ODN 1 (scrambled ODN)” instead of “. . . lane 4, HUVEC treated with 0.5 μ M ODN 1 (scrambled ODN); lane 5, HUVEC treated with 0.5 μ M ODN 4 (antisense ODN)” as printed. For the reader’s convenience, the corrected Fig. 3 and the corrected legend are printed below.

This erratum is doi:10.1006/bbrc.2000.3887.




FIG. 3. Effect of ODNs directed against caveolin-1 mRNA evaluated by RT-PCR. RNA was isolated from HUVEC treated with 0.5 μ M ODN 1 and ODN 4. The 510 bp β -actin fragment (detectable in lanes 2 and 3) and the 564 bp caveolin-1 fragment (detectable in lanes 4 and 5) were obtained by amplification of 100 ng cDNA in the conditions reported under Materials and Methods. Lane 1, PhiX 174 DNA/Hinf I marker (Promega, USA); lane 2, HUVEC treated with 0.5 μ M ODN 1 (scrambled ODN); lane 3, HUVEC treated with 0.5 μ M ODN 4 (antisense ODN); lane 4, HUVEC treated with 0.5 μ M ODN 4 (antisense ODN); lane 5, HUVEC treated with 0.5 μ M ODN 1 (scrambled ODN).

Volume **276**, Number 3 (2000), in the article “D-Aspartate in a Prolactin-Secreting Clonal Strain of Rat Pituitary Tumor Cells (GH₃),” by Zhiqung Long, Jen-Ai Lee, Taizo Okamoto, Noriyuki Nimura, Kazuhiro Imai, and Hiroshi Homma, pages 1143–1147 (doi:10.1006/bbrc.2000.3573): On page 1145, in the legend to Fig. 2, the second sentence should read “GH₃ cells cultured in DMEM for 4 days were probed with anti-D-Asp antiserum (B) and preabsorbed antiserum (A) by the method described under Materials and Methods” instead of